Improved Survival with Bevacizumab in Advanced Cervical Cancer

20141,486 citationsJournal Articlebronze Open Access

Authors

Krishnansu S. Tewari · University of California, Irvine Medical Center

Michael W. Sill · University at Buffalo, State University of New York

Harry J. Long

Richard T. Penson · Massachusetts General Hospital

Helen Huang · University at Buffalo, State University of New York

Lois M. Ramondetta · The University of Texas MD Anderson Cancer Center

Lisa M. Landrum · Oklahoma City University

Abstract

The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).

Topics & Keywords

Endometrial and Cervical Cancer Treatments Angiogenesis and VEGF in Cancer Colorectal and Anal Carcinomas

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 8, pp. 734-743

DOI: 10.1056/nejmoa1309748

Field-Weighted Citation Impact: 122.06